NO20083002L - Fremgangsmate for anvendelse av CD40-bindende forbindelser - Google Patents

Fremgangsmate for anvendelse av CD40-bindende forbindelser

Info

Publication number
NO20083002L
NO20083002L NO20083002A NO20083002A NO20083002L NO 20083002 L NO20083002 L NO 20083002L NO 20083002 A NO20083002 A NO 20083002A NO 20083002 A NO20083002 A NO 20083002A NO 20083002 L NO20083002 L NO 20083002L
Authority
NO
Norway
Prior art keywords
binding compounds
treatment
binding
binding agents
associated diseases
Prior art date
Application number
NO20083002A
Other languages
English (en)
Inventor
Jonathan Drachman
Che-Leung Law
Tim Lewis
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of NO20083002L publication Critical patent/NO20083002L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Sammendrag Fremgangsmåter for anvendelse av CD40-bindende midler for behandling av CD40 assosierte sykdommer.
NO20083002A 2005-12-09 2008-07-03 Fremgangsmate for anvendelse av CD40-bindende forbindelser NO20083002L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74924605P 2005-12-09 2005-12-09
US81135306P 2006-06-05 2006-06-05
US81130106P 2006-06-05 2006-06-05
US84723406P 2006-09-25 2006-09-25
PCT/US2006/047308 WO2007075326A2 (en) 2005-12-09 2006-12-11 Methods of using cd40 binding agents

Publications (1)

Publication Number Publication Date
NO20083002L true NO20083002L (no) 2008-08-14

Family

ID=38218421

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083002A NO20083002L (no) 2005-12-09 2008-07-03 Fremgangsmate for anvendelse av CD40-bindende forbindelser

Country Status (11)

Country Link
US (1) US20090304687A1 (no)
EP (1) EP1968636A4 (no)
JP (1) JP2009518441A (no)
KR (1) KR20080079301A (no)
AU (1) AU2006329944A1 (no)
BR (1) BRPI0619586A2 (no)
CA (1) CA2632698A1 (no)
IL (1) IL191990A0 (no)
MX (1) MX2008007140A (no)
NO (1) NO20083002L (no)
WO (1) WO2007075326A2 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP5559695B2 (ja) * 2007-11-09 2014-07-23 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
AU2009206506B2 (en) * 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
CA2758523C (en) 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
PT2683406T (pt) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e utilização dos mesmos
EP3508500A1 (en) 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40 antibodies and methods of use
CN104159921B (zh) 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN104918957B (zh) * 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11059898B2 (en) 2014-03-24 2021-07-13 Cancer Research Technology Limited Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
SG11201702598XA (en) 2014-10-29 2017-05-30 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
IL300548A (en) 2015-05-20 2023-04-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
EA036789B1 (ru) 2015-06-22 2020-12-22 Янссен Байотек, Инк. Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN116063481A (zh) * 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
TWI800341B (zh) 2015-11-03 2023-04-21 美商健生生物科技公司 抗cd38抗體之皮下調配物及其用途
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
EP3806848A2 (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
WO2022266496A1 (en) * 2021-06-17 2022-12-22 Parker Institute For Cancer Immunotherapy Methods of treating kras mutation subtypes with cd40 agonist
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1276849A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
DE60239931D1 (de) * 2001-04-02 2011-06-16 Genentech Inc Kombinationstherapie
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
MXPA06011796A (es) * 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
RU2006140374A (ru) * 2004-04-16 2008-05-27 Дженентек, Инк. (Us) Лечение нарушений
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use

Also Published As

Publication number Publication date
BRPI0619586A2 (pt) 2018-08-28
KR20080079301A (ko) 2008-08-29
EP1968636A2 (en) 2008-09-17
IL191990A0 (en) 2008-12-29
MX2008007140A (es) 2009-03-04
US20090304687A1 (en) 2009-12-10
WO2007075326A3 (en) 2008-09-04
CA2632698A1 (en) 2007-07-05
EP1968636A4 (en) 2010-06-02
JP2009518441A (ja) 2009-05-07
AU2006329944A1 (en) 2007-07-05
WO2007075326A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NL301145I2 (nl) Tirbanibulin
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EA200802213A1 (ru) Способы лечения заболеваний крови
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
EA200971077A1 (ru) Гетероциклические модуляторы киназы
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
EA201070247A1 (ru) Ингибиторы протеасом
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
EA201170521A1 (ru) Новые соединения
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application